Search clinical trials for: Spiolto Respimat

Total 127 results

Boehringer Ingelheim

Completed

Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto® Respimat® (AERIAL®)

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy (OTIVACTO)

Pulmonary Disease, Chronic Obstructive

Italy
Boehringer Ingelheim

Completed

Greek NIS Spiolto ELLACTO

Pulmonary Disease, Chronic Obstructive

Greece
Boehringer Ingelheim
HealthCore-NERI

Completed

Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Terminated

Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO)

Pulmonary Disease, Chronic Obstructive

Belgium, Luxembourg, Netherlands, Denmark, Portugal, Sweden
Boehringer Ingelheim

Completed

A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler

Pulmonary Disease, Chronic Obstructive

Israel, Russian Federation, Ukraine, Bulgaria, Czechia, Hungary, Lithuania, Poland, Romania, Slovenia, Switzerland
Boehringer Ingelheim

Completed

Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD Patients

Pulmonary Disease, Chronic Obstructive

China
Boehringer Ingelheim

Completed

Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)

Pulmonary Disease, Chronic Obstructive

Germany
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor

Malignancy

China
Boehringer Ingelheim

Terminated

Ventilator Adapters for Combivent Respimat

Pulmonary Disease, Chronic Obstructive

United States
Università degli Studi di Ferrara

Terminated

Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Italy
Boehringer Ingelheim

Completed

Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Japan
University of Dundee

Completed

Ultra-long Acting Bronchodilator Therapy in Smoking Asthmatics (MAN05)

Asthma

United Kingdom
Lundquist Institute for Biomedical Innovation at...
Boehringer Ingelheim

Completed

The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
Boehringer Ingelheim

Completed

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Cardiovascular Function in COPD Patients

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Re-usable Respimat® Soft MistTM Inhaler Study

Pulmonary Disease, Chronic Obstructive

Denmark, Netherlands, Finland, Belgium, Germany, Norway
Boehringer Ingelheim

Completed

Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece

Pulmonary Disease, Chronic Obstructive

Greece
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BEA 2180 BR in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Withdrawn

Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone

Asthma
Lawson Health Research Institute
Heart and Stroke Foundation of Canada

Recruiting

Identifying Therapeutic Hemodialysis Targets Through Cerebrovascular Reactivity; RESPIRACT 2 (RESPIRACT 2)

Chronic Kidney Failure

Canada
Boehringer Ingelheim

Withdrawn

Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroids

Asthma
Boehringer Ingelheim

Withdrawn

TARA Working Prototype [Version 2]: Feasibility Study

Pulmonary Disease, Chronic Obstructive
RWTH Aachen University

Withdrawn

Cardiac Effects of Spiolto®/Respimat® in Patients With Congestive Heart Failure and COPD (CREATES)

COPD

Germany
Indiana University

Not yet recruiting

Utilizing Carbon Dioxide for Assessing Coronary Blood Flow in Subjects With Coronary Artery Disease (NIMO-CAD)

Coronary Artery Disease

United States
Duke University

Suspended

Alternate Methodology of Pulse Oximeter Validation

Hypoxemia | Desaturation of Blood

United States
Boehringer Ingelheim

Completed

Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data

Pulmonary Disease, Chronic Obstructive

China
University of Toronto
University Health Network, Toronto; Thornhill Research

Unknown

The Response of Intraocular Pressure to Systemic Hypercapnia and Hyperoxia

Intraocular Pressure

Canada
Şeyhmus KAPLAN

Completed

Hyaluronic Acid, Corticosteroid and Electrotherapy in Subacromial Impingement Syndrome

Subacromial Impingement | Pain, Shoulder
Indiana University

Not yet recruiting

Needle Free Assessment of Myocardial Oxygenation in Healthy Subjects (NIMO-Healthy)

Coronary Artery Disease

United States
Boehringer Ingelheim
Pfizer

Completed

Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma

Asthma

United States, Chile, Germany, Hungary, Italy, Korea, Republic of, Latvia, Mexico, Russian Federation, Slovakia, Spain, Ukraine
University of Dundee
Boehringer Ingelheim; NHS Tayside

Completed

INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol (INCOGNITO)

Chronic Obstructive Pulmonary Disease

United Kingdom
San Diego State University
Patient-Centered Outcomes Research Institute

Unknown

Imperial County Asthma CER Project: Respira Sano (Respira Sano)

Asthma

United States
Fundacion Clinic per a la Recerca Biomédica

Not yet recruiting

Evaluation of the Therapeutic Usability of RESPIRA ADVANCED Device in Patients Under Invasive Mechanical Ventilation (RESPIRA-02)

Respiratory Insufficiency

Spain
Auckland University of Technology
Ministry of Business, Innovation and Employment; Waikato District Health Board

Not yet recruiting

RespirAq Humidifier Usability During Invasive Ventilation

Mechanical Ventilation
Boehringer Ingelheim

Completed

A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Tiotropium Bromide in Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Hungary, Ireland, Israel, Italy, Poland, Portugal, Russian Federation, Slovakia, South Africa, Spain, Switzerland, United Kingdom
University of Calgary

Recruiting

Hypercapnia and Orthostatic Tolerance in Postural Orthostatic Tachycardia Syndrome

Orthostatic Intolerance | Postural Tachycardia Syndrome

Canada
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BEA 2180 BR in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study

Pulmonary Disease, Chronic Obstructive

United States
Erasme University Hospital

Completed

Effects of Acute Long-acting Bronchodilation on Oxygenation and Peripheral Ventilation in COPD

Pulmonary Disease, Chronic Obstructive

Belgium
Boehringer Ingelheim

Completed

Safety and Efficacy of Berodual® Respimat® Compared to Berodual® MDI (Metered Dose Inhaler) in Asthma Patients

Asthma
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma

Asthma

Japan
Boehringer Ingelheim

Completed

A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
Lashmi Venkatraghavan
University Health Network, Toronto

Completed

Optic Nerve Sheath Diameter (ONSD) With the Raised PCO2 and Internal Jugular Venous Occlusion

Elevated Intracranial Pressure (ICP)

Canada
Boehringer Ingelheim

Completed

Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Efficacy and Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide in Symptomatic Adult Moderate to Severe Asthmatics Requiring Inhaled Corticosteroids and Bronchodilator Therapy

Asthma
Boehringer Ingelheim

Completed

Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, France, Greece, Korea, Republic of, New Zealand, Poland, Russian Federation, South Africa, Taiwan, Turkey, Ukraine, United Kingdom
Boehringer Ingelheim

Completed

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

Pulmonary Disease, Chronic Obstructive

Germany, Italy, Switzerland, South Africa

3

Subscribe